Bicycle Therapeutics plc
NASDAQ: BCYC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kevin Lee
- Employees
- 305
- Headquarters
- Cambridge, United Kingdom
- IPO year
- 2019
- Market cap
- $274.8M
- Website
- https://www.bicycletherapeutics.com
Loading BCYC…
Loading profile data…Frequently asked questions about BCYC
What does Bicycle Therapeutics plc (BCYC) do?
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I...
Where does BCYC trade?
Bicycle Therapeutics plc (BCYC) trades on the NASDAQ Global Select.
What sector is BCYC in?
Bicycle Therapeutics plc (BCYC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bicycle Therapeutics plc?
Kevin Lee is the chief executive officer of Bicycle Therapeutics plc (BCYC).
Where is Bicycle Therapeutics plc headquartered?
Bicycle Therapeutics plc is headquartered in United Kingdom.
Does BCYC pay a dividend?
Bicycle Therapeutics plc (BCYC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BCYC go public?
Bicycle Therapeutics plc (BCYC) completed its initial public offering in 2019.
Is BCYC an ADR?
Yes — BCYC is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Bicycle Therapeutics plc reporting and dividends follow the underlying issuer.